2 types of pain relief in 2 types of arthritis

Researchers have examined the efficacy of upadacitinib and adalimumab in patients with arthritis-associated pain.

In a post hoc analysis of two Phase 3 trials published in RMD Open, the researchers compared the pain-related outcomes following treatment with upadacitinib or adalimumab versus placebo among patients with rheumatoid arthritis or psoriatic arthritis.

Upadacitinib was found to be more effective in attenuating pain among patients with rheumatoid arthritis compared with adalimumab and placebo, whereas among patients with psoriatic arthritis, upadacitinib and adalimumab had comparable accuracy and were more effective compared with placebo.

The findings suggested that upadacitinib may both suppress inflammation and address noninflammatory pain in patients with rheumatoid arthritis.

Read more: RMD Open

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.